Literature DB >> 1902992

A randomized clinical trial of ampicillin, gentamicin and clindamycin versus cefotaxime and clindamycin in children with ruptured appendicitis.

K P Schropp1, S Kaplan, E S Golladay, D R King, W Pokorny, D L Mollitt, W E Wise, E O Mason.   

Abstract

This prospective, randomized, double-blind study compares the efficacy, safety and cost-effectiveness of ampicillin, gentamicin and clindamycin (AGC) or cefotaxime and clindamycin (CC) for the treatment of children with complicated appendicitis. Ninety-seven children were randomized. Forty-seven were assigned to the AGC regimen and 50 received CC. Forty-two patients in the AGC group had an appropriate therapeutic outcome, whereas 48 of 50 children who received CC completed the trial successfully (p = NS). There were no differences between the groups with reference to the duration of antibiotic administration, fever, leukocytosis or length of hospitalization. Complications of therapy were uncommon and neither regimen demonstrated a significant advantage from an economic standpoint. We concluded that, in childhood, complicated appendicitis can be treated with either CC or AGC with equal efficacy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902992

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  3 in total

1.  Preoperative administration of antibiotics in patients with suspected acute appendicitis.

Authors:  Y Murao; S Ueda; S Miyamoto
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

2.  Abscess after a laparoscopic appendectomy presenting as low back pain in a professional athlete.

Authors:  Lisa R Witkin; Hien T Nguyen; Charles E Silberstein; Laura M Fayad; Edward G McFarland
Journal:  Sports Health       Date:  2011-01       Impact factor: 3.843

Review 3.  Outcome reporting in randomised controlled trials and meta-analyses of appendicitis treatments in children: a systematic review.

Authors:  Nigel J Hall; Mufiza Z Kapadia; Simon Eaton; Winnie W Y Chan; Cheri Nickel; Agostino Pierro; Martin Offringa
Journal:  Trials       Date:  2015-06-17       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.